ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1566

The Efficacy and Safety of Biological Disease Modifying Anti-Rheumatic Drugs and Apremilast in the Treatment of Psoriatic Arthritis: A Systematic Review and Meta-Analysis

Arthur N. Lau1, Michael Zoratti2, Alfred Cividino3, William Bensen3, Jonathan D. Adachi3 and Christopher Edwards4, 1Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 2Clinical Epidemiology and Biostatistics, Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, 3Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 4Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologic drugs and psoriatic arthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II

Session Type: Abstract Submissions (ACR)

Background/Purpose

Currently, there are a number of effective therapies for psoriatic arthritis (PsA). The objective of this systematic review was to assess the efficacy (PSARC, ACR 20/50/70 and PASI75 response) and adverse event profile (AEs) (any AEs, serious AEs, and infection rate) of using TNF inhibitors or new therapies including Ustekinumab and Apremilast to treat active PsA.

Methods

This review included all published/unpublished RCTs comparing biologics or Apremilast to placebo in PsA patients. Multiple mechanisms of action (MOA) were included: TNF inhibitor (Adalimumab, Certolizumab, Etanercept, Infliximab and Golimumab), IL12/23 inhibitor(Ustekinumab) and PDE4 inhibitor(Apremilast). The databases MEDLINE(n=245), EMBASE(n=1551) and CENTRAL(n=223) were searched. Conference abstracts from the ACR and American Academy of Dermatology (2009-13) were hand searched. Two reviewers independently screened titles/abstracts/full text for eligibility. Data extraction and risk of bias assessment were performed in duplicate using Cochrane’s Risk of Bias Assessment.

Results

18 studies (5433 participants) were included. Kappa for full text and risk of bias was 0.8545 and 0.9217 respectively. When the MOAs were pooled, the risk ratio (RR) for achieving PSARC, ACR20,50,70, and PASI75 at 12-16 and 24 weeks(wk) were all statistically significant. The likelihood of achieving the primary outcome ACR20 (12-16wk) had RR=2.74(95%CI=2.27-3.32) with significant heterogeneity (I2= 65%) which was explained by a priori subgroup analysis (by MOA). When comparing the ACR20 (12-16wk) response by MOA, the RR was 3.99 (95%CI: 2.91-5.46), 2.03 (95%CI: 1.70-2.42) and 2.08 (95%CI: 1.66-2.59) respectively for the TNF, PDE4 and IL12/23 inhibitors. RR of achieving ACR20 response (24wk) by MOA is shown in figure1. Low heterogeneity (I2<40%) was seen for the outcomes ACR50,70 at 12-16/24wk respectively, suggesting there may be comparable efficacy of each MOA class for these outcomes. There was no significant increase in risk for any AEs or severe AEs, except a mild increase in risk of infections at 24wk (RR=1.15, 95%CI= 1.00-1.32).

Conclusion

TNF inhibitors, Ustekinumab & Apremilast all appear to produce significant benefits on joint and skin disease for individuals with PsA.  The safety profile, aside from a slight increased risk of infections, appears acceptable. When comparing the three MOAs, the TNF inhibitors appeared most effective in achieving an ACR20 response at 12-16wk. However, by 24wk there was no significant difference between TNF inhibition and Apremilast while a significant difference remained between TNF inhibition and Ustekinumab. Whilst head to head trials are needed to definitively draw such conclusions, incorporating additional RCTs in future analyses will provide greater power to characterize this relationship.

Fig1: RR for achieving ACR20 response (24wk) vs placebo by MOA


Disclosure:

A. N. Lau,

Amgen, Roche,

2,

Amgen, Roche,

8,

Amgen, Roche,

2;

M. Zoratti,
None;

A. Cividino,

Celgene, Abbvie,

5;

W. Bensen,

Janssen Inc.,

5;

J. D. Adachi,
None;

C. Edwards,

Celgene Corporation, Pfizer Inc, Roche, and Samsung,

2,

Celgene Corporation, Pfizer Inc, Roche, and Samsung,

5,

Abbott, Glaxo-SmithKline, Pfizer Inc, and Roche,

8.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-efficacy-and-safety-of-biological-disease-modifying-anti-rheumatic-drugs-and-apremilast-in-the-treatment-of-psoriatic-arthritis-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.